Skip to content
  • About Us
  • Privacy Policy
  • Contact Us
B2B Newz

B2B Newz

Daily Industry News & Updates

  • Top Stories
  • Business
  • Technology
  • Health
  • Science
  • Toggle search form
FDA Uncertainty Takes Its Toll On Bioshares

FDA Uncertainty Takes Its Toll On Bioshares

Posted on March 18, 2019 By Nicholas Miller

The surprising announcement by Commissioner of Food and Drug Administration of US that he will be stepping down from his role next month has created chaos in the biotech sector forcing the industry to face its worst ever decline in share markets. Biotech analysts say that this was due to shock in the industry about how his exit will affect small innovation driven biotech firms. The Nasdaq Biotech Index which is traded heavily fell by 5% within three days of the announcement by FDA commissioner Scott Gottlieb. The NYSE Arca Biotech Index for large caps fell by 4% during the same period.

Analysts say that biotech investors are concerned that without the expert leadership of Gottlieb the agency is likely to lose its momentum on the efforts being made to pressurize pharma companies to open up their processes for creation of biosimilar drugs that are in reality the generic equivalent of novel drugs. Under the leadership of Gottlieb FDA had managed to get around 59 drugs approved in one year along with obtaining clearances for introduction of 971 generic drugs including launch of generic versions of critical medical tools like EpiPen and asthma treatment inhaler Advair.

Though there is hope that introduction of drugs in the line of gene therapy and cell therapy may get approved with the same speed as now but generic approvals for drugs might slow down. The fast pace of drug approval under the outgoing commissioner had also been a cause for concern as it was leading to underperformance in generic drug sector and significant erosion in prices and margins as per a recent research note submitted by S&P analysts. According to experts two generic drug making companies namely Teva pharmaceuticals and Mylan could benefit from the slowdown in generic drug approvals after the departure of FDA commissioner.

Top Stories

Post navigation

Previous Post: Popular Paris Street Want To Shun Instagrammers
Next Post: Medication Made Affordable Through Employer-Sponsored Plans By UnitedHealth

Related Posts

NHS Encourages People To Know Their BP, Cholesterol Levels NHS Encourages People To Know Their BP, Cholesterol Levels Top Stories
Over 400 Channels Terminated By YouTube After Controversy Of Child Exploitation Over 400 Channels Terminated By YouTube After Controversy Of Child Exploitation Top Stories
Inactivated HIV Persisting In Patients’ Cells Can Be Measured With Accuracy Inactivated HIV Persisting In Patients’ Cells Can Be Measured With Accuracy Health
Chromebook App Hub Offers Teachers Ideas For Classroom Activities Chromebook App Hub Offers Teachers Ideas For Classroom Activities Top Stories
Venezuela Sees A Surge In Insect Inflicted Diseases Venezuela Sees A Surge In Insect Inflicted Diseases Top Stories
Medication Made Affordable Through Employer-Sponsored Plans By UnitedHealth Medication Made Affordable Through Employer-Sponsored Plans By UnitedHealth Top Stories

Follow us

follow us

Recent Posts

  • Ultraviolet Overexposure can now be detected via the world’s smallest, battery-free, wearable device
  • Global Automotive Collision Repair Services Market Set to Register at CAGR 3.4% During 2020–2026
  • Concrete Block and Brick Manufacturing Market Growing Demand by Major Competitor and Strategies Analysis in 2029
  • Global Wind Turbine Operations and Maintenance Market Size Will Reach $21 Billion By 2028
  • Complementary and Alternative Medicine Market Outlook, Status, Trends 2022

Who We Are

Every day, people staying around, are looking for information to better understand their journey towards future. Recognizing the challenge of finding a trusted local source of news and information, B2B News is a trusted destination for news impacting with the precise fusion of trust, reliability, genuine information crafted in the inspiring stories and many other forms of information.

Get In Touch With us

B2B News Update
2717 Wilmarco Ave,
Baltimore, MD 21223, USA
Phone: +1 410-941-6063
Email: contact@b2bnewz.com

b2bnewsUpdate_logo

Copyright © 2022 B2B Newz.

Powered by PressBook Media WordPress theme